REGENERX : RGN-457 for Cystic Fibrosis

October 01, 2008 - REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced that it is seeking a strategic partner to assist in the development of RGN-457 for the treatment of cystic fibrosis (CF). RGN-457 is based on thymosin beta 4 (TB4) peptide formulated as an inhaled therapeutic agent to address this patient population. CF is a life-threatening, hereditary disease that impairs the patient's ability to breathe due to the accumulation of thick and sticky mucus secretions in the airways of the lungs. There are estimated to be 30,000 and 40,000 CF patients in the U.S. and Europe, respectively. It is, therefore, considered an "orphan" disease in both territories. In 2006, the predicted median age of survival for patients with cystic fibrosis was 37 years... REGENERX BIOPHARMACEUTICALS' Press Release -

RegeneRx : First Patent on TB4's Ability to Repair Lung Damage Resulting from Infections and Other Disorders

June 24, 2008 — RegeneRx Receives First Patent on TB4's Ability to Repair Lung Damage Resulting from Infections and Other Disorders - RegeneRx Biopharmaceuticals, Inc. (AMEX: RGN) announced that it has received an Australian patent for the use of TB4, its derivatives, analogues and fragments, to repair pulmonary damage resulting from pulmonary microbial infections. The patent expires in 2023.
TB4 is a synthetic version of a biologically active, naturally occurring peptide that has been shown, in pre-clinical studies, to be effective in accelerating dermal, ophthalmic, and myocardial wound healing. TB4 may also be important in other areas of tissue and organ repair, as well as tissue protection. RegeneRx is currently sponsoring five clinical trials and expects to report data later this year on several of these studies... RegeneRx Biopharmaceuticals' Press Release -